Real-World Clinical Outcomes in Relapsed/Refractory Multiple Myeloma Treated With Pomalidomide Regimens

This retrospective observational study will use data from the OneOncology United States database to evaluate clinical outcomes in adults with relapsed/refractory multiple myeloma who received pomalidomide-containing or non-pomalidomide-containing treatment as second-line or third-line therapy after prior exposure to lenalidomide and a proteasome inhibitor.

NCT Number	NCT07689006
Lead Sponsor	Bristol-Myers Squibb
Conditions	Relapsed/Refractory Multiple Myeloma
Enrollment	341 participants
Start Date	2024-12-23
Primary Completion	2025-03-28 (estimated)
Study Completion	2025-03-28 (estimated)
Updated on ClinicalTrials.gov	2026-07-07